ArchPoint Investors’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-4,402
| Closed | -$263K | – | 77 |
|
|
2021
Q3 | $263K | Buy |
+4,402
| New | +$290K | 0.08% | 81 |
|
|
2021
Q2 | – | Sell |
-900
| Closed | -$57K | – | 55 |
|
|
2021
Q1 | $57K | Hold |
900
| – | – | 0.02% | 100 |
|
|
2020
Q4 | $56K | Hold |
900
| – | – | 0.02% | 96 |
|
|
2020
Q3 | $54K | Hold |
900
| – | – | 0.02% | 91 |
|
|
2020
Q2 | $53K | Hold |
900
| – | – | 0.02% | 94 |
|
|
2020
Q1 | $50K | Sell |
900
-820
| -48% | -$50.1K | 0.02% | 109 |
|
|
2019
Q4 | $110K | Hold |
1,720
| – | – | 0.03% | 102 |
|
|
2019
Q3 | $87K | Hold |
1,720
| – | – | 0.03% | 94 |
|
|
2019
Q2 | $78K | Hold |
1,720
| – | – | 0.02% | 99 |
|
|
2019
Q1 | $82K | Hold |
1,720
| – | – | 0.02% | 100 |
|
|
2018
Q4 | $89K | Hold |
1,720
| – | – | 0.03% | 84 |
|
|
2018
Q3 | $107K | Hold |
1,720
| – | – | 0.03% | 103 |
|
|
2018
Q2 | $95K | Sell |
1,720
-65,859
| -97% | -$3.56M | 0.03% | 102 |
|
|
2018
Q1 | $4.27M | Sell |
67,579
-149
| -0.2% | -$9.59K | 1.26% | 18 |
|
|
2017
Q4 | $4.15M | Sell |
67,728
-1
| -0% | -$63 | 1.29% | 17 |
|
|
2017
Q3 | $4.32M | Sell |
67,729
-500
| -0.7% | -$29.2K | 1.38% | 16 |
|
|
2017
Q2 | $3.8M | Sell |
68,229
-4,191
| -6% | -$228K | 1.21% | 18 |
|
|
2017
Q1 | $3.94M | Sell |
72,420
-11,100
| -13% | -$609K | 1.48% | 13 |
|
|
2016
Q4 | $4.88M | Hold |
83,520
| – | – | 2.87% | 9 |
|
|
2016
Q3 | $4.5M | Hold |
83,520
| – | – | 2.57% | 13 |
|
|
2016
Q2 | $6.14M | Buy |
83,520
+2,500
| +3% | +$177K | 3.51% | 6 |
|
|
2016
Q1 | $5.18M | Buy |
81,020
+25,000
| +45% | +$1.58M | 2.84% | 5 |
|
|
2015
Q4 | $3.85M | Sell |
56,020
-4,250
| -7% | -$281K | 2.71% | 9 |
|
|
2015
Q3 | $3.57M | Buy |
60,270
+2,600
| +5% | +$165K | 2.47% | 8 |
|
|
2015
Q2 | $3.84M | Buy |
57,670
+14,370
| +33% | +$947K | 2.4% | 7 |
|
|
2015
Q1 | $2.79M | Sell |
43,300
-3,500
| -7% | -$219K | 1.9% | 13 |
|
|
2014
Q4 | $2.76M | Hold |
46,800
| – | – | 2.05% | 12 |
|
|
2014
Q3 | $2.4M | Hold |
46,800
| – | – | 2.03% | 13 |
|
|
2014
Q2 | $2.27M | Sell |
46,800
-150
| -0.3% | -$7.39K | 1.91% | 15 |
|
|
2014
Q1 | $2.44M | Buy |
46,950
+1,465
| +3% | +$78K | 2.2% | 13 |
|
|
2013
Q4 | $2.42M | Buy |
45,485
+565
| +1% | +$28.8K | 2.2% | 12 |
|
|
2013
Q3 | $2.08M | Buy |
44,920
+470
| +1% | +$20.6K | 2.29% | 14 |
|
|
2013
Q2 | $1.99M | Buy |
+44,450
| New | +$1.93M | 2.34% | 11 |
|
Other funds holding BMY
ArchPoint Investors's BMY Position: Q4 2021 in Review
ArchPoint Investors sold out of Bristol-Myers Squibb (BMY) in Q4 2021, closing a stake of 4,402 shares — an estimated $263K sold.
ArchPoint Investors first reported a position in BMY in Q2 2013 and held it in 33 quarters. The position peaked at $6.14M in Q2 2016. 2,445 funds tracked by Wall St. Rank hold BMY as of Q4 2021.
- ArchPoint Investors reported no remaining Bristol-Myers Squibb position as of Q4 2021 after selling out during the quarter.
- ArchPoint Investors sold 4,402 Bristol-Myers Squibb shares in Q4 2021, an estimated $263K.
- ArchPoint Investors first reported a position in Bristol-Myers Squibb in Q2 2013 and held it in 33 quarters.
- ArchPoint Investors's Bristol-Myers Squibb position peaked at $6.14M in Q2 2016.
- 2,445 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q4 2021.
Based on ArchPoint Investors's 13F filing for Q4 2021, filed 11 Feb 2022.